| 0.02 0 (0%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.04 |
1-year : | 0.05 |
| Resists | First : | 0.03 |
Second : | 0.05 |
| Pivot price | 0.02 |
|||
| Supports | First : | 0.01 |
Second : | 0.01 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.02 |
| MA(100) : | 0.07 |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 18.6 |
D(3) : | 21.1 |
| RSI | RSI(14): 28.3 |
|||
| 52-week | High : | 6.69 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRPH ] has closed above bottom band by 5.0%. Bollinger Bands are 67.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Sat, 05 Sep 2026
ProPhase Labs stock trades quietly as investors look to recent diagnostics performance - ad-hoc-news.de
Fri, 14 Aug 2026
ProPhase Labs (PRPH) cites auditor review delays for late Q2 2026 10-Q filing - Stock Titan
Sat, 25 Jul 2026
ProPhase Labs, Inc. Revenue Breakdown – OTC:PRPH - tradingview.com
Wed, 01 Jul 2026
ProPhase Labs, Inc. (PRPH) Q1 2026 10-Q: Financials, Stock Info, and Key SEC Filing Details - Minichart
Mon, 01 Jun 2026
ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary - tradingview.com
Tue, 17 Mar 2026
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 16 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.04 |
| Profit Margin | 0 % |
| Operating Margin | -261.7 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -539.7 % |
| Qtrly Rev. Growth | -18.9 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.24 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.36 |
| Price to Sales | 0.05 |
| Price to Cash Flow | -0.04 |
| Dividend | 3 |
| Forward Dividend | 0 |
| Dividend Yield | 21428.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|